W hen BioNTech agreed to acquire rival messenger RNA company CureVac in a $1.25 billion stock deal earlier this summer, some ...

NHS England's collaboration with BioNTech is crucial in discovering individuals who may benefit from the trial.

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

IO Biotech (IOBT) stock rallies as cancer vaccine, Cylembio, with Merck's (MRK) Keytruda outperforms in a late-stage trial ...

CureVac ( (CVAC)) has provided an announcement. On August 7, 2025, CureVac announced the resolution of U.S. patent litigation with Pfizer/BioNTech concerning mRNA-based COVID-19 vaccines. As part of ...

NIH Director Jay Bhattacharya offered an explanation for the cancellation of mRNA vaccine contracts that didn't align with ...

After the success of the Phase Ib study, Assembly Bio’s herpes therapy will advance to Phase II trials in mid-2026.

Discover key insights from Roivant Sciences' Q1 2025 earnings call, including brepocitinib DM data milestones, financial strength, and strategic ...

Are women somehow missing from the future of innovation? New research suggests that gender bias may be quietly shaping the ...

IO Biotech’s cancer vaccine has “narrowly” failed to beat Merck's blockbuster oncology drug Keytruda in a phase 3 melanoma ...

Q1 2025 Management View CEO Matthew Gline described the quarter as "relatively quiet" ahead of an "exciting, busy fall," ...

The word from the FDA is that Prasad has come back at the request of the regulator's Commissioner, Marty Makary, who ...